Research

Focus on the pharmaceutical and biotech industry
Douglas Paul, PhD Discusses the Orphan Drug Act

Douglas Paul, PhD Discusses the Orphan Drug Act

Douglas Paul, PharmD, PhD discusses the Orphan Drug Act and the issue of whether Pharma and Biotech companies are "gaming the system," when bringing drugs or devices before the FDA. The FDA Office of Orphan Products Development (OOPD) aims to advance the development...

Gorlin Syndrome Overview

Gorlin Syndrome Overview

Jean Tang, MD, PhD is co-founder of PellePharm and serves on the PellePharm board of directors. She is a practicing dermatologist and associate professor of dermatology at Stanford University.

Dr. Cohen, CEO of Corbus Pharma, Discussing Lenabasum

Dr. Cohen, CEO of Corbus Pharma, Discussing Lenabasum

https://www.youtube.com/watch?v=YGvQNDXCRWg Yuval Cohen, PhD, CEO of Corbus discusses the company's lead drug candidate Lenabasum. Lenabasum (formerly known as anabasum) is a synthetic, oral, small-molecule, selective cannabinoid receptor type 2 (CB2) agonist that...

Jeff Marrazzo Discusses His Company’s Hemophilia Portfolio

Jeff Marrazzo Discusses His Company’s Hemophilia Portfolio

Jeff Marrazzo is Co-Founder and CEO of Spark Therapeutics. In this video, he discusses his company's investigational gene therapy programs focused on Hemophilia. Hemophilia is most typically a rare genetic bleeding disorder that causes a delay in clot formation as a...

Thijs Spoor of AzurRx Provides an Overview of Cystic Fibrosis

Thijs Spoor of AzurRx Provides an Overview of Cystic Fibrosis

Thijs Spoor of AzurRx Provides an Overview of Cystic Fibrosis Cystic fibrosis (CF) is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 worldwide) have CF. In...

Biglyca: An Emerging Therapy for Duchenne Muscular Dystrophy

Biglyca: An Emerging Therapy for Duchenne Muscular Dystrophy

Justin Fallon, PhD is the Scientific Founder and Director of Tivorsan Pharmaceuticals, discusses Biglycan as an emerging therapy for Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Biglycan is a small, naturally occurring extracellular matrix protein naturally found in muscle.

The Bio CEO & Investor Conference

The Bio CEO & Investor Conference

The 2018 BIO CEO & Investor Conference took place in New York City on February 12-13 in New York City. This Conference remains one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies....

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.